Warning: The NCBI web site requires JavaScript to function. more...
Developments in the scientific and clinical understanding of gout.
So A.
Arthritis Res Ther. 2008;10(5):221. Epub 2008 Oct 10. Review.
Related citations
[New knowledge on the pathophysiology and therapy of gout].
Z Rheumatol. 2007 Nov;66(7):562, 564-7. Review. German.
[Recent advances in the pathophysiology of hyperuricemia and gout].
Rev Med Suisse. 2007 Mar 21;3(103):720, 722-4. Review. French.
Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals.
Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R.
J Immunol. 2006 Nov 1;177(9):6370-8.
Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival.
Martin WJ, Grainger R, Harrison A, Harper JL.
J Rheumatol. 2010 Jun;37(6):1228-35. Epub 2010 Apr 15.
Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout.
Martin WJ, Walton M, Harper J.
Arthritis Rheum. 2009 Jan;60(1):281-9.
Gout: epitome of painful arthritis.
VanItallie TB.
Metabolism. 2010 Oct;59 Suppl 1:S32-6. Review.
Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process.
Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J, Kullberg BJ, Netea MG, van der Meer JW.
Ann Rheum Dis. 2009 Feb;68(2):273-8. Epub 2008 Apr 4.
Overview of hyperuricaemia and gout.
Masseoud D, Rott K, Liu-Bryan R, Agudelo C.
Curr Pharm Des. 2005;11(32):4117-24. Review.
Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis.
Tramontini N, Huber C, Liu-Bryan R, Terkeltaub RA, Kilgore KS.
Arthritis Rheum. 2004 Aug;50(8):2633-9.
NALP3 inflammasome functional polymorphisms and gout susceptibility.
Miao ZM, Zhao SH, Yan SL, Li CG, Wang YG, Meng DM, Zhou L, Mi QS.
Cell Cycle. 2009 Jan 1;8(1):27-30. Epub 2009 Jan 31.
Gout.
Pascual E, Pedraz T.
Curr Opin Rheumatol. 2004 May;16(3):282-6. Review.
Gout: new insights into an old disease.
Martinon F, Glimcher LH.
J Clin Invest. 2006 Aug;116(8):2073-5.
Recent advances in crystal-induced acute inflammation.
Akahoshi T, Murakami Y, Kitasato H.
Curr Opin Rheumatol. 2007 Mar;19(2):146-50. Review.
PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR, Saifer MG, Perez-Ruiz F.
Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14. Review.
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Dalbeth N, Merriman T.
Rheumatology (Oxford). 2009 Mar;48(3):222-6. Epub 2008 Dec 24. Review.
Update on gout: new therapeutic strategies and options.
Terkeltaub R.
Nat Rev Rheumatol. 2010 Jan;6(1):30-8. Review.
[Crystal-induced activation of the inflammasome: gout and pseudogout].
Winzer M, Tausche AK, Aringer M.
Z Rheumatol. 2009 Nov;68(9):733-9. German.
Gout-associated uric acid crystals activate the NALP3 inflammasome.
Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J.
Nature. 2006 Mar 9;440(7081):237-41. Epub 2006 Jan 11.
Febuxostat: a new agent for lowering serum urate.
Keenan RT, Pillinger MH.
Drugs Today (Barc). 2009 Apr;45(4):247-60. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on